Pluristem to expand R&D of radiation exposure treatment

Following preliminary discussions with several governmental authorities, Pluristem Therapeutics (NASDAQ:PSTI; TASE:PLTR) plans to expand its research and development efforts on an acute radiation exposure treatment. Dr. Liat Flaishon, recently appointed as director of business development, will lead the company’s development efforts. Pluristem’s placental 3D expanded cells have demonstrated efficacy as mitigators of the acute radiation [...]

Rodman ups Alnylam price target to $19

Rodman & Renshaw has raised its year-end price target for “market outperform-rated” Alnylam Pharmaceuticals (NASDAQ:ALNY) to $19 from $12, based on changes to the company’s business model and a sum-of-the-parts analysis. Noting that Alnylam has made considerable progress in its clinical development programs in the past six months, analyst Michael King writes that he has [...]

D. Medical CEO interviewed on Bloomberg TV

Efri Argaman, CEO of D. Medical Industries (NASDAQ, TASE:DMED), was interviewed today by Sara Eisen on Bloomberg Television’s “InsideTrack.” Mr. Argaman discussed a host of topics, ranging from the state of the U.S. diabetes market, regulatory oversight and D. Medical’s sales strategy in the U.S. Instead of setting up a direct and costly U.S. sales [...]

Cipher achieves sales milestone for Lipofen

Cipher Pharmaceuticals (TSX:DND) has reached a sales milestone for Lipofen, its fenofibrate product, triggering a $1 million payment from Kowa Pharmaceuticals America, the company’s U.S. marketing and distribution partner. The one-time milestone, which is based on sales performance over a trailing 12-month period, reflects a steady increase in new prescriptions during the past quarter. Cipher’s [...]

GeneNews in pact for first personalized medicine center in China

GeneNews (TSX:GEN) has signed a memorandum of understanding with Shanghai Biochip, a leading Chinese engineering center for advanced microarray and gene expression profiling technologies, for a strategic alliance to establish the first Sentinel Centre for Personalized Medicine in China. GeneNews and SBC would jointly establish and manage the Sentinel Centre for Personalized Medicine to co-develop [...]

BioLineRx in-licenses second oral Hepatitis C treatment

BioLineRx (NASDAQ, TASE:BLRX) has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally candidate to treat Hepatitis C virus (HCV). The agreement includes upfront license fees, milestones and royalties payable to both companies, which terms are consistent with BioLineRx’s standard in-license agreements. BL-8030 is a potent [...]

pSivida CEO to participate at glaucoma conference

pSivida (NASDAQ:PSDV; ASX:PVA) CEO Dr. Paul Ashton will participate today in a panel: New Horizons in Glaucoma Drug Delivery and IOP Monitoring during the Glaucoma 360 New Horizons forum at the Palace Hotel in San Francisco. The conference is being presented by the Glaucoma Research Foundation in association with Ophthalmology Times to bring together leaders [...]

Rodman to launch automated electronic transaction platform

Rodman & Renshaw Capital Group (NASDAQ:RODM), via a new subsidiary, DirectMarkets, has unveiled an automated, state-of-the-art electronic transaction platform to directly link existing public company issuers and investors seeking to transact primary offerings of securities. Both investors and issuers will benefit from 24/7 seamless access to DirectMarkets’ platform through a graphical user interface accessible via computer [...]

Navidea to seek approval for Lymphoseek in Europe

Navidea Biopharmaceuticals (AMEX:NAVB) intends to file a Marketing Authorization Application (MAA) in the EU for Lymphoseek, its radioactive diagnostic tracing agent, based on clinical data accumulated from completed pivotal studies and supporting clinical literature. Navidea also has been advised by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use that it has [...]

Roth upgrades Antares Pharma to buy

Roth Capital Partners has upgraded Antares Pharma (AMEX:AIS) to “buy” from “neutral” and raised its 12-month price target to $3.50 from $2, saying the balance sheet is strong and the company could become cash flow positive this year. “The solid financial position, platform opportunities, and potential for advancement of key products make the stock attractive [...]

Next Page »